In 2010, Ariad declared outcome from the phase I analyze of ponatinib in individuals with resistant and refractory Persistent myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Heart Attack, Stroke, and Loss of life. Xeljanz can boost your threat of a coronary